Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886433 | 0.83 | ALDH1A1 (0.54) | HRH3ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL27056901 | 0.82 | KDM4E (0.47) | KDM4EAOC3HRH3SIGMAR1ALDH1A1 | |
| SCHEMBL24300628 | 0.82 | KDM4E (0.36) | KDM4EAOC3HRH3SIGMAR1ALDH1A1 | |
| SCHEMBL8080450 | 0.80 | HTT (0.41) | KDM4EAOC3TSHR | |
| SCHEMBL22702644 | 0.79 | ALDH1A1 (0.42) | ALDH1A1TSHR | |
| SCHEMBL18279459 | 0.79 | ALDH1A1 (0.58) | KDM4EHRH3SIGMAR1ALDH1A1CYP3A4 | |
| SCHEMBL22388176 | 0.78 | OPRM1 (0.46) | KDM4EAOC3SIGMAR1TAAR1BCHE | |
| SCHEMBL22388183 | 0.77 | ESRRG (0.38) | AOC3ALDH1A1TDP1BCHE | |
| SCHEMBL21153502 | 0.77 | HRH3 (0.35) | KDM4EAOC3HRH3ALDH1A1CYP3A4 | |
| SCHEMBL20323571 | 0.77 | HPGD (0.41) | KDM4EALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885AOC3 3941/4885HRH3 3387/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885AOC3 3941/4885HRH3 3387/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885AOC3 3941/4885HRH3 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.